Geron is developing first-in-class biopharmaceuticals for the treatment of cancer and chronic degenerative diseases, including spinal cord injury, heart failure and diabetes. We are advancing an anti-cancer drug and a cancer vaccine that target the enzyme telomerase through multiple clinical trials. We are also the world leader in the development of human embryonic stem cell-based therapeutics.
We have received FDA clearance to begin the world's first human clinical
trial of a hESC-based therapy: GRNOPC1 for acute spinal cord injury.
